Targeting of the Hedgehog/GLI and mTOR pathways in advanced pancreatic cancer, a phase 1 trial of Vismodegib and Sirolimus combination.

Authors

Ryan M Carr
Narjust Duma
Angela L McCleary-Wheeler
Luciana L Almada
David L Marks
Rondell P Graham
Thomas C Smyrk
Val Lowe
Mitesh J Borad
George Kim, George Washington University
Geoffrey B Johnson
Jacob B Allred
Jun Yin
Vun-Sin Lim
Tanios Bekaii-Saab
Wen We Ma
Charles Erlichman
Alex A Adjei
Martin E Fernandez-Zapico

Document Type

Journal Article

Publication Date

7-14-2020

Journal

Pancreatology: Official Journal of the International Association of Pancreatology (IAP)

DOI

10.1016/j.pan.2020.06.015

Comments

Online ahead of print

APA Citation

Carr, R., Duma, N., McCleary-Wheeler, A., Almada, L., Marks, D., Graham, R., Smyrk, T., Lowe, V., Borad, M., Kim, G., Johnson, G., Allred, J., Yin, J., Lim, V., Bekaii-Saab, T., Ma, W., Erlichman, C., Adjei, A., & Fernandez-Zapico, M. (2020). Targeting of the Hedgehog/GLI and mTOR pathways in advanced pancreatic cancer, a phase 1 trial of Vismodegib and Sirolimus combination.. Pancreatology: Official Journal of the International Association of Pancreatology (IAP), (). http://dx.doi.org/10.1016/j.pan.2020.06.015

Peer Reviewed

1